Kinomica

Kinomica is a private, pre-revenue diagnostics company leveraging its proprietary KScan® phosphoproteomic platform to guide cancer treatment decisions. By mapping the active signaling networks in a tumor, the platform aims to answer critical clinical questions about optimal therapy selection and drug repurposing for non-responders. The company is led by a seasoned team with expertise in biotech entrepreneurship, diagnostics strategy, and mass spectrometry, positioning it to address a significant gap in functional precision oncology.

KScan®, a phosphoproteomic diagnostic platform using mass spectrometry to map activated signaling pathways in patient tumors to guide therapy selection and drug repurposing.

Kinomica competes with large, entrenched genomic profiling companies (e.g., Foundation Medicine) and a growing field of multi-omic and functional diagnostic startups. Its differentiation lies in its exclusive focus on phosphoproteomics to provide a dynamic, functional readout of pathway activation, a layer of biology not captured by DNA or RNA sequencing alone.